メインコンテンツにスキップ

希少疾患医薬品開発の加速に秀でる

By: Rajesh Krishna, PhD, FAAPS and Steve Sibley According to the National Institutes of Health, more than 30 million people in the United States are affected by a rare disease. Defined in the Orphan Drug Act as any disease that affects less than 200,000 people in the United States, rare diseases total more than 7,000 … Continued

Certara Shanghai relocates to a new location and sets sail for a new era

Certara Shanghai relocated the office and held a grand opening ceremony at Hong Kong Plaza in Huangpu District, Shanghai on 2022年9月9日. The goal of this move was to provide greater support to local customers  and facilitate meeting market needs. Customers and key opinion leaders in China were invited to the ceremony where they … Continued

Certara to Host Second Annual Symposium Dedicated to Advancing Pediatric Drug Development

PRINCETON, N.J., 2022年9月25日 – Certara, a global leader in biosimulation, today announced it will host the second annual New Horizons in Pediatric Drug Development Symposium from October 27-28, 2022. The two-day virtual symposium brings together global thought leaders from academia, industry, patient advocacy organizations and health authorities to discuss the latest innovations in … Continued

Certara Announces Second Year of Fellowship Program in Africa for Applied Pharmacometrics Training

PRINCETON, N.J.— 2022年9月25日 — Certara, Inc, a global leader in biosimulation, today announced that it is expanding its Applied Pharmacometrics Training (APT) fellowship program for doctoral-level scientists from Africa, in partnership with Pharmacometrics Africa, CP+ Associates, and other industry and academic partners.  After its successful first year with sixteen fellows, the program has … Continued

Certara Hosts Seminar on Drug Discovery Challenges in Japan and How Modeling and Simulation Can Solve Them

“Quantitative decision-making with data rather than empirical thinking” – Certara’s Modeling & Simulation technology contributes to accelerate new drug development Certara G.K. held an online press seminar on 2022年8月31日 (水曜日), in Tokyo, on the optimization of the drug development process and the role of a drug discovery consulting company. In Japan, local demand … Continued

The Challenging Road to Developing an Integrated Platform for Drug Discovery and Precision Medicine Using the Power of Pharmacometrics

We have often seen Dr. Hwi-yeol (Thomas) Yun, Associate Professor/Adjunct Professor at the College of Pharmacy and Bio-AI Convergence Research Center of Chungnam National University, listed as a guest presenter at key Pharmacometrics conferences across the Asia-Pacific region, as well as at local Korean events. In 2020, he also presented to a large audience at … Continued

Getting Results Faster – Supporting Physicians and Pharmacists with Biosimulation Technologies

Certara’s Phoenix biosimulation software platform is widely used for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and population PK analysis. Recently, we have seen how Certara software helps customers accelerate collaboration across their divisions and groups for better clinical results. Today, we interviewed Sun Hua, Associate Chief Pharmacist at Yijishan Hospital, Drug Evaluation Center, Wannan Medical College, … Continued

サターラがPinnacle21(ピナクル21)の買収を完了

<i>医薬品開発プロセスを加速し成功へと導くテクノロジーの強化</i><i><i>プリンストン、ニュージャージー:2021年10月4日</i></i> バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced the completion of the previously announced transaction to acquire Pinnacle 21, a leading provider of SaaS solutions for clinical data fitness, regulatory compliance and submission readiness.  … Continued

1 of 13
Powered by Translations.com GlobalLink OneLink Software